Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
TLR9/MyD88/TRIF signaling activates host immune inhibitory CD200 in Leishmania infection
Ismael P. Sauter, … , Wadih Arap, Mauro Cortez
Ismael P. Sauter, … , Wadih Arap, Mauro Cortez
Published May 16, 2019
Citation Information: JCI Insight. 2019;4(10):e126207. https://doi.org/10.1172/jci.insight.126207.
View: Text | PDF
Research Article Infectious disease

TLR9/MyD88/TRIF signaling activates host immune inhibitory CD200 in Leishmania infection

  • Text
  • PDF
Abstract

Virulent protozoans named Leishmania in tropical and subtropical areas produce devastating diseases by exploiting host immune responses. Amastigotes of Leishmania amazonensis stimulate macrophages to express CD200, an immunomodulatory ligand, which binds to its cognate receptor (CD200R) and inhibits the inducible nitric oxide synthase and nitric oxide (iNOS/NO) signaling pathways, thereby promoting intracellular survival. However, the mechanisms underlying CD200 induction in macrophages remain largely unknown. Here, we show that phagocytosis-mediated internalization of L. amazonensis amastigotes following activation of endosomal TLR9/MyD88/TRIF signaling is critical for inducing CD200 in infected macrophages. We also demonstrate that Leishmania microvesicles containing DNA fragments activate TLR9-dependent CD200 expression, which inhibits the iNOS/NO pathway and modulates the course of L. amazonensis infection in vivo. These findings demonstrate that Leishmania exploits TLR-signaling pathways not only to inhibit macrophage microbicidal function, but also to evade host systemic immune responses, which has many implications in the severity of the disease.

Authors

Ismael P. Sauter, Katerine G. Madrid, Josiane B. de Assis, Anderson Sá-Nunes, Ana C. Torrecilhas, Daniela I. Staquicini, Renata Pasqualini, Wadih Arap, Mauro Cortez

×

Figure 1

Macrophage CD200 expression induced by Leishmania amazonensis requires phagocytosis of viable parasites.

Options: View larger image (or click on image) Download as PowerPoint
Macrophage CD200 expression induced by Leishmania amazonensis requires p...
(A) BMMs infected with axenic (Axe) or lesion (Les) amastigotes of L. amazonensis for 1 hour. (B) BMMs pretreated with cytochalasin D (Cyto-D) and infected (+) or not (–) with lesion amastigotes for 1 hour. CD200 protein levels analyzed by IP/Western blot. Actin from IP-input sample served as loading control. (C) Representative immunofluorescence images of the amastigote in vitro infection, showing attached (blue arrowheads) or internalized (white arrowheads) parasites. Amastigotes were stained sequentially with anti-Leishmania antibodies and anti–rabbit IgG Alexa Fluor 488 (green). Nuclei were stained with propidium iodide (red). (D) Percentage of the attached (white bars) or internalized (black bars) amastigote infection after Cyto-D treatment in BMMs. Results correspond to the mean ± SD of 3 independent experiments. **P < 0.01 (2-way ANOVA). (E) Total number of amastigotes in infected BMMs pretreated or not with cytochalasin. The data correspond to the mean ± SD of triplicates. Results expressed as amastigotes per 100 infected BMMs representative of 3 independent experiments. (F) IP/Western blot of CD200 in samples from BMMs incubated with live or dead amastigotes (either by PFA or heat treatment). (G) Representative images of BMMs incubated with live or dead amastigotes and processed as in C. Scale bars: 10 μm (C and G). (H) Percentage of infection for attached (white bars) or internalized (black bars) amastigotes for the in vitro assay shown in E. At least 300 cells per coverslip were counted for each assay. Results correspond to the mean ± SD of 3 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts